Free tool
FAERS Monitor: Depo-Medrol
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 011757 or its brand name (Depo-Medrol, Methylprednisolone Acetate). Reports on generic versions are filed under their own applications.
Reports
8,121
Serious
6,901
85% of reports
Hospitalization
2,646
Death reported
1,047
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pain1,628
- off label use1,337
- drug ineffective1,334
- rheumatoid arthritis1,294
- fatigue1,220
- headache1,137
- joint swelling967
- nausea824
- arthralgia780
- drug hypersensitivity772
- rash766
- pyrexia736
- drug intolerance703
- malaise678
- hypersensitivity665
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 102 |
| 2005 | 103 |
| 2006 | 130 |
| 2007 | 103 |
| 2008 | 126 |
| 2009 | 174 |
| 2010 | 307 |
| 2011 | 290 |
| 2012 | 376 |
| 2013 | 272 |
| 2014 | 192 |
| 2015 | 311 |
| 2016 | 327 |
| 2017 | 353 |
| 2018 | 355 |
| 2019 | 563 |
| 2020 | 554 |
| 2021 | 376 |
| 2022 | 519 |
| 2023 | 527 |
| 2024 | 717 |
| 2025 | 891 |
| 2026 | 453 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,038 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| rheumatoid arthritisSignal | 1,294 | 29.8 | 28.4 | 35,833 |
| joint swellingSignal | 967 | 20.9 | 19.7 | 18,268 |
| drug intoleranceSignal | 703 | 19.0 | 17.7 | 11,923 |
| drug hypersensitivitySignal | 772 | 10.4 | 9.7 | 6,560 |
| hypersensitivitySignal | 665 | 9.3 | 8.7 | 4,949 |
| painSignal | 1,628 | 6.9 | 6.6 | 8,398 |
| pyrexiaSignal | 736 | 5.5 | 5.2 | 2,758 |
| arthralgiaSignal | 780 | 4.9 | 4.6 | 2,435 |
| headacheSignal | 1,137 | 4.7 | 4.5 | 3,408 |
| rashSignal | 766 | 4.6 | 4.3 | 2,165 |
| fatigueSignal | 1,220 | 4.1 | 3.9 | 2,918 |
| malaiseSignal | 678 | 4.0 | 3.7 | 1,558 |
| off label useSignal | 1,337 | 4.0 | 3.8 | 3,078 |
| nauseaSignal | 824 | 2.7 | 2.5 | 912 |
| drug ineffectiveSignal | 1,334 | 2.6 | 2.5 | 1,426 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.